论文部分内容阅读
目的:探讨沙利度胺联合DICE化疗方案治疗复发性弥漫性大B细胞淋巴瘤的疗效。方法:26例非霍奇金淋巴瘤患者,男14例,女12例均为应用RCHOP方案化疗达到完全缓解后(CR)的复发病例,其病理组织学及免疫组化均为弥漫性大B细胞淋巴瘤。采取沙利度胺与DICE化疗方案联合应用。结果:完全缓解(CR)12例,部分缓解(PR)5例,总有效率65.4%。结论:沙利度胺联合DICE化疗方案治疗复发性弥漫性大B细胞淋巴瘤有效率高,改善了患者的近期和远期生存,应用相对安全,值得临床进一步研究。
Objective: To investigate the efficacy of thalidomide combined with DICE chemotherapy in the treatment of recurrent diffuse large B cell lymphoma. Methods: Twenty-six non-Hodgkin’s lymphoma patients, including 14 males and 12 females, were all recurred after complete remission (CR) with RCHOP regimen. The histopathology and immunohistochemistry were diffuse large B Cell lymphoma. To take thalidomide and DICE chemotherapy in combination. Results: Complete remission (CR) in 12 cases, partial remission (PR) in 5 cases, the total effective rate was 65.4%. CONCLUSION: Thalidomide and DICE chemotherapy are effective in treating recurrent diffuse large B cell lymphoma and improve the short-term and long-term survival of patients. The application of thalidomide combined with DICE is relatively safe and deserves further clinical study.